Cargando…

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Patnaik, M M, Wassie, E A, Padron, E, Onida, F, Itzykson, R, Lasho, T L, Kosmider, O, Finke, C M, Hanson, C A, Ketterling, R P, Komrokji, R, Tefferi, A, Solary, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349260/ https://www.ncbi.nlm.nih.gov/pubmed/25679292 http://dx.doi.org/10.1038/bcj.2015.9

Ejemplares similares

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
por: Patnaik, M M, et al.
Publicado: (2016)

Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia
por: Lasho, T L, et al.
Publicado: (2015)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
por: Patnaik, M M, et al.
Publicado: (2017)

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Chesnais, Virginie, et al.
Publicado: (2012)

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
por: Padron, E, et al.
Publicado: (2015)

Blast Phase Chronic Myelomonocytic Leukemia: Mayo-MDACC Collaborative study of 171 cases
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study
por: Greenberg, A J, et al.
Publicado: (2015)

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
por: Duchmann, Matthieu, et al.
Publicado: (2018)

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
por: Cerquozzi, S., et al.
Publicado: (2017)

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet
por: Itzykson, Raphael, et al.
Publicado: (2018)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
por: Patnaik, M M, et al.
Publicado: (2010)

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy
por: Gangat, Naseema, et al.
Publicado: (2019)

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
por: Barraco, D, et al.
Publicado: (2016)

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
por: Barraco, D, et al.
Publicado: (2016)

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

MPL-mutated essential thrombocythemia: a morphologic reappraisal
por: Szuber, Natasha, et al.
Publicado: (2018)

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)
por: Tefferi, Ayalew, et al.
Publicado: (2017)

Genetic predictors of response to specific drugs in primary myelofibrosis
por: Penna, Domenico, et al.
Publicado: (2018)

P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Binder, Moritz, et al.
Publicado: (2023)

Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
por: Binder, Moritz, et al.
Publicado: (2022)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
por: Vallapureddy, Rangit R., et al.
Publicado: (2019)

Tracking chronic myelomonocytic leukaemia diversity at the single cell level
por: Solary, Eric
Publicado: (2020)

Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases
por: Gangat, Naseema, et al.
Publicado: (2022)

Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia
por: Pophali, Prateek A., et al.
Publicado: (2019)

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
por: Pardanani, A, et al.
Publicado: (2012)

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Erratum to: A prospective multicenter cohort study of frailty in younger critically ill patients
por: Bagshaw, Sean M., et al.
Publicado: (2016)

Ovarian cancer in younger vs older women: a population-based analysis
por: Chan, J K, et al.
Publicado: (2007)

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents
por: Duchmann, M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j4bebpsp23flke8kiqkk9upie6